Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Biological/Vaccine: ET140203 autologous T-cell product Autologous T cells transduced with lentivirus encoding an ET140203 expression construct”In the company’s words, NCT04634357 on ClinicalTrials.gov
- Tested for
- Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS
- Main trialPhase 1/2
- “Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.”In the company’s words, NCT04634357 on ClinicalTrials.gov
Other drugs for Hepatoblastoma
- CobolimabGSK · Phase 1/2
- DostarlimabGSK · Phase 1/2
- VAL-413Valent Technologies, LLC · Phase 1
Coming up1
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2027 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma | |
| Phase 1Terminated | 30 Aug 2024 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026